<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04859452</url>
  </required_header>
  <id_info>
    <org_study_id>HA1118-CSP-010</org_study_id>
    <nct_id>NCT04859452</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects</brief_title>
  <official_title>A Four-part, Single-center, Open-label, Phase I Clinical Study to Evaluate the Drug-Drug Pharmacokinetic Interaction Between DBPR108 at Steady-state and Metformin Hydrochloride/Glibenclamide/Valsartan/ Simvastatin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a four-part, single-center, open-label, single-sequence crossover phase I clinical&#xD;
      study to characterize the Drug-Drug Interaction (DDI) potential of DBPR108 at steady-state&#xD;
      with Metformin hydrochloride, Glibenclamide, Valsartan, or Simvastatin in Healthy Subjects.&#xD;
      This study also aims to evaluate the safety and tolerability of DBPR108 in the presence of&#xD;
      Metformin hydrochloride, Glibenclamide, Valsartan, or Simvastatin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DBPR108 is a potent dipeptidylpeptidase-4 inhibitor. This study will be run in four parts to&#xD;
      characterize the Drug-Drug Interaction (DDI) potential of DBPR108 with the expected&#xD;
      concomitant drugs (Metformin hydrochloride, Glibenclamide, Valsartan, Simvastatin) in Healthy&#xD;
      Subjects. Each part of this study consists of a screening period (Day -14 to Day -1), a&#xD;
      baseline period (Day -1), a treatment period (Day 1 to Day 9), and a follow-up visit on Day&#xD;
      15. Approximately 14 subjects will be enrolled in each part of this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Actual">July 9, 2021</completion_date>
  <primary_completion_date type="Actual">July 3, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The pharmacokinetic parameters of Metformin, Glibenclamide, Valsartan, Simvastatin, Simvastatin acid and DBPR108</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The pharmacokinetic parameters of Metformin, Glibenclamide, Valsartan, Simvastatin, Simvastatin acid and DBPR108</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetic parameters</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>The pharmacokinetic parameters (Metformin, Glibenclamide, Valsartan, Simvastatin, Simvastatin acid, DBPR108) : Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetic parameters</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>The pharmacokinetic parameters (Metformin, Glibenclamide, Valsartan, Simvastatin, Simvastatin acid, DBPR108) : t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetic parameters</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>The pharmacokinetic parameters (Metformin, Glibenclamide, Valsartan, Simvastatin, Simvastatin acid, DBPR108) : Vz/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetic parameters</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>The pharmacokinetic parameters (Metformin, Glibenclamide, Valsartan, Simvastatin, Simvastatin acid, DBPR108) : CL/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of volunteers with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Day 1 to Day 15</time_frame>
    <description>The number of volunteers with adverse events as a measure of safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>The DDI of DBPR108 tablets and Metformin hydrochloride tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of metformin hydrochloride on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of metformin hydrochloride on Day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The DDI of DBPR108 tablets and Glibenclamide tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of Glibenclamide on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of Glibenclamide on Day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The DDI of DBPR108 tablets and Valsartan Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of Valsartan on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of Valsartan on Day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The DDI of DBPR108 tablets and Simvastatin tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of Simvastatin on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of Simvastatin on Day 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DBPR108 tablets</intervention_name>
    <description>Drug: DBPR108, tablet, oral</description>
    <arm_group_label>The DDI of DBPR108 tablets and Glibenclamide tablets</arm_group_label>
    <arm_group_label>The DDI of DBPR108 tablets and Metformin hydrochloride tablets</arm_group_label>
    <arm_group_label>The DDI of DBPR108 tablets and Simvastatin tablets</arm_group_label>
    <arm_group_label>The DDI of DBPR108 tablets and Valsartan Capsules</arm_group_label>
    <other_name>DBPR108</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin hydrochloride tablets</intervention_name>
    <description>Drug: Metformin hydrochloride, tablet, oral</description>
    <arm_group_label>The DDI of DBPR108 tablets and Metformin hydrochloride tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glibenclamide tablets</intervention_name>
    <description>Drug: Glibenclamide, tablet, oral</description>
    <arm_group_label>The DDI of DBPR108 tablets and Glibenclamide tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan Capsules</intervention_name>
    <description>Drug: Valsartan, capsule, oral</description>
    <arm_group_label>The DDI of DBPR108 tablets and Valsartan Capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin tablets</intervention_name>
    <description>Drug: Simvastatin, tablet, oral</description>
    <arm_group_label>The DDI of DBPR108 tablets and Simvastatin tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntarily sign the informed consent form, understand the trial procedures, and be&#xD;
             willing to comply with all trial procedures and restrictions；&#xD;
&#xD;
          -  18 years to 45 years (inclusive), male or female；&#xD;
&#xD;
          -  Male subjects weight ≥50 kg and female subjects weight ≥45 kg. Body mass index (BMI) :&#xD;
             18-30 kg/m2 (inclusive) (BMI= weight (kg)/height 2 (m2))；&#xD;
&#xD;
          -  Subjects (including partners) are willing to use effective contraceptives from&#xD;
             screening to the 6 months after the last dose administration；&#xD;
&#xD;
          -  Be judged to be in good health by the investigator, based on the physical examination,&#xD;
             vital sign examination, 12-lead electrocardiogram (ECG) examination and laboratory&#xD;
             examination；&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have a history of allergic conditions (such as asthma, urticaria), or&#xD;
             have a history of allergy to two or more drugs or food, or may be allergic to the test&#xD;
             drug and the related compounds;&#xD;
&#xD;
          -  Have a history of severe diseases, such as cardiovascular, respiratory, liver,&#xD;
             gastrointestinal, endocrine, hematologic, mental/nervous systems diseases within 1&#xD;
             year prior to screening；&#xD;
&#xD;
          -  Subjects who have previously undergone surgery that may affect drug absorption,&#xD;
             distribution, metabolism, or excretion (e.g., subtotal gastrectomy), or who have a&#xD;
             scheduled surgical plan during the study period;&#xD;
&#xD;
          -  Use of any prescription drug, over-the-counter drug, or herbal medicine within 2 weeks&#xD;
             prior to screening;&#xD;
&#xD;
          -  Drug abuse, or positive urine drug screen at screening；&#xD;
&#xD;
          -  Smoking more than 5 cigarettes per day within 3 months prior to screening；&#xD;
&#xD;
          -  Average alcohol intake is more than 28g alcohol (male) or 14g (female) per week (14g ≈&#xD;
             497mL beer, or 44mL spirits with low alcohol content, or 145mL wine) within the 3&#xD;
             months prior to screening, or taking any alcohol within 48 hours before dosing, or a&#xD;
             positive ethanol breath test at screening；&#xD;
&#xD;
          -  Consumption of grapefruit juice, Methylxanthine-rich food or beverage (such as coffee,&#xD;
             tea, cola, chocolate, energy drinks) within 48 hours before the administration, or&#xD;
             have strenuous exercise, or have other factors affecting drug absorption,&#xD;
             distribution, metabolism, excretion, etc；&#xD;
&#xD;
          -  Participation in another clinical trial within 3 months before screening；&#xD;
&#xD;
          -  Blood donation (or blood loss) ≥400 mL, or receiving whole blood transfusions or&#xD;
             erythrocyte suspension transfusions within 3 months prior to the screening；&#xD;
&#xD;
          -  The patients who have undergone comprehensive inspection with any significant clinical&#xD;
             significant in physical examination (vital signs, physical examination), routine&#xD;
             laboratory examination (blood routine, blood biochemical examination, urine routine),&#xD;
             chest X-ray (anteroposterior), abdominal B (liver, bile, pancreas, spleen and kidney)&#xD;
             and other examinations, as judged by the investigator;&#xD;
&#xD;
          -  Have a positive test result of hepatitis B surface antigen, hepatitis C antibody,&#xD;
             anti-human immunodeficiency virus antibody or anti-Treponema pallidum specific&#xD;
             antibody;&#xD;
&#xD;
          -  A pregnant/lactating woman, or has a positive pregnancy test at screening or during&#xD;
             the trial.；&#xD;
&#xD;
          -  Not suitable for this study as judged by the investigator；&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Glyburide</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

